3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Sarcoma, Ewing
2
Sarcoma
2
Ovarian Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Rare Diseases
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neoplasms, Connective and Soft Tissue
1
Neoplasms, Connective Tissue
1
Neoplasms, Bone Tissue
1
Neoplasms by Histologic Type
1
Neoplasms
1
Lymphoma, Follicular
1
Lymphoma
1
Kidney Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Ovarian Epithelial
1
Interventions
ponatinib
4
pembrolizumab
3
Rituximab
3
Gemcitabine
3
Cyclophosphamide
3
130-nm albumin-bound paclitaxel
3
pralsetinib
2
napabucasin
2
Vincristine
2
Prednisone
2
Irinotecan
2
Imatinib Mesylate
2
Etoposide
2
Doxorubicin
2
Carboplatin
2
Brentuximab Vedotin
2
tetulomab tetraxetan lu-177
1
ruxolitinib
1
ricolinostat
1
pomalidomide
1
pamiparib
1
nirogacestat
1
nilotinib
1
ibritumomab tiuxetan
1
denileukin diftitox
1
bosutinib
1
blinatumomab
1
Vorinostat
1
Temozolomide
1
Radiation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Neoplasms by Histologic Type
×
FANG vaccine
×
Clear all
NCT03495921
2023-04-26
VITA
Gradalis, Inc.
Phase 3
Terminated
32 enrolled
13 charts